Loading...
XASXDXB
Market cap111mUSD
Dec 27, Last price  
0.32AUD
1D
0.00%
1Q
-16.88%
Name

Dimerix Ltd

Chart & Performance

D1W1MN
XASX:DXB chart
P/E
—
P/S
305.95
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.92%
Rev. gr., 5y
-16.62%
Revenues
583k
-93.51%
1,369,138564655,993756,9570073,068088,973350,218238,053610,272554,617845,2881,447,3902,340,9544,439,7156,463,4558,983,737583,478
Net income
-17m
L+23.71%
-595,797-11,161,018-2,421,661-3,557,390-4,128,738-347,7675,656-386,070-517,098-527,978-679,539-5,254,475-1,758,532-3,319,726-2,886,221-4,494,153-6,371,734-10,490,579-13,802,819-17,075,083
CFO
-7m
L-43.06%
0-2,013,892-1,656,7420000000-558,550-1,379,129-1,864,407-3,225,432-2,750,802-4,721,480-6,462,778-13,437,335-12,730,504-7,248,282
Dividend
Sep 24, 19990.0078125 AUD/sh
Earnings
Feb 24, 2025

Profile

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
URL
https://dimerix.com/
IPO date
Jul 05, 1989
Employees
0
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
583
-93.51%
8,984
38.99%
6,463
45.58%
Cost of revenue
25,643
22,823
16,908
Unusual Expense (Income)
NOPBT
(25,060)
(13,840)
(10,445)
NOPBT Margin
Operating Taxes
(7,932)
(8,935)
(6,033)
Tax Rate
NOPAT
(17,128)
(4,905)
(4,412)
Net income
(17,075)
23.71%
(13,803)
31.57%
(10,491)
64.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
25,707
8,280
18,200
BB yield
-11.13%
-41.03%
-50.63%
Debt
Debt current
(495)
5,958
52
Long-term debt
219
22
42
Deferred revenue
10,417
Other long-term liabilities
43
38
30
Net debt
(22,417)
(2,012)
(9,536)
Cash flow
Cash from operating activities
(7,248)
(12,731)
(13,437)
CAPEX
(16)
(2)
(11)
Cash from investing activities
(16)
(2)
(11)
Cash from financing activities
21,415
11,071
17,692
FCF
(19,814)
(3,976)
(8,046)
Balance
Cash
22,141
7,992
9,630
Long term investments
Excess cash
22,112
7,543
9,307
Stockholders' equity
18,186
5,963
14,423
Invested Capital
10,610
5,996
5,219
ROIC
ROCE
EV
Common stock shares outstanding
452,910
325,529
299,535
Price
0.51
722.58%
0.06
-48.33%
0.12
-38.46%
Market cap
230,984
1,044.46%
20,183
-43.85%
35,944
-8.47%
EV
208,567
18,171
26,409
EBITDA
(25,011)
(13,784)
(10,394)
EV/EBITDA
Interest
1
Interest/NOPBT